In-Person Event |
Baker McKenzie Offices,
Level 46, Tower 1,
100 Barangaroo Avenue,
Barangaroo NSW
Overview (Program Summary)
A program hosted by:
ACC AustraliaWe invite you to the much-anticipated launch of the Health Law Network!
(Doors open 4.00pm for 4:30pm start, networking drinks from 6.00pm)
The Health Law Network (HLN) is a subset of ACC members who are in-house legal counsel supporting the healthcare industry: public, private, pharma, devices, doctors, and patients.
This event is crafted for in-house counsel navigating the dynamic healthcare sector, and will feature Q&A discussion on a range of topics, with distinguished experts in the field. The session will provide you with the opportunity to become better informed, explore pressing issues and future directions for Australian healthcare.
Key Topics for Discussion
+ Key Issues: What are the most pressing challenges facing the healthcare system in Australia today?
+ Advancements: Is the system keeping pace with developments in medicines and medical technology?
+ Patient Interests: Are Australian patients' needs being prioritised amidst these changes?
+ Technology Impact: What are the implications of new technologies for the healthcare system and patients?
+ Health Data: Is transparency in health data a benefit or a burden?
As legal professionals, your role in advocating for change, supporting new initiatives and emerging technologies is vital. This forum, sponsored by Baker McKenzie, will foster a broader discussion beyond legal risks, enabling in-house lawyers to contribute value and take a leadership role in the ongoing transformation of healthcare delivery in Australia.
Speakers
Kevin Barrow, CEO, Sydney North Health Network
Prior to joining Sydney North Health Network as the CEO, Kevin was the CEO of the Butterfly Foundation, the national charity for all Australians impacted by eating disorders and body image issues. Kevin has more than 25 years of experience in the healthcare industry. As Managing Director for Philips Australia and New Zealand, Kevin oversaw all of Philips’ businesses and its supporting operations across Australia and New Zealand. He joined Philips from the medical technology firm BD (Becton, Dickinson, and Company) where he was the Managing Director for Australia and New Zealand. Kevin was appointed to the Board of the Medical Technology Association of Australia (MTAA) in 2009-2010 and served as the Chair from 2012-2014. Kevin is a non-executive board member of Cyclopharm, an Australian diagnostic nuclear medicine company. Born in New Zealand, Kevin holds a Master of Science (with 1st Class Honours) from Waikato University, New Zealand. He obtained an MBA from the Macquarie Graduate School of Management, Sydney, Australia and is a graduate of the Australian Institute of Company Directors and is an Adjunct Fellow at Macquarie University.
Professor Shaun Larkin, Professor in Health Policy and Financing, The University of Sydney
Professor Shaun Larkin joined the School of Public Health at the University of Sydney as Professor in Health Policy and Financing in January 2018. In addition to this academic role, over the past seven years, Shaun has leveraged his experience at HCF (see below) to become an investor, director and/or advisor to several start-ups in the health start-up ecosystem in Australia and the United States.
Shaun has also undertaken several commissioned consulting roles over the last seven years, through his company WIKV Advisory, for entities as diverse as a number of large Federal Government Departments; multi-national medical device manufactures; health service delivery companies; consulting groups; and financial services providers in both Australia and Asia.
Before taking up his University of Sydney role Shaun worked at The Hospitals Contribution Fund of Australia (HCF) as a General Manager in a number of executive roles (Strategic Development; Benefits Management; Corporate Ventures; and Operations) before, in 2009, being appointed to the role of Managing Director. Shaun served in the role for eight years. Prior to joining HCF, Shaun was based in Singapore for four years where he led the establishment of a chain of ambulatory medical centres throughout Asia and the CIS. Before this he worked for eight years as an executive for a large private hospital operator (Ramsay Health Care) in Australia and the United States.
An alumnus of Harvard Business School, his academic qualifications include a HlthScD, MHSc, and MBA.
Jennifer Mulheron, General Counsel & Company Secretary, Harrison.ai
Jen Mulheron is the General Counsel & Company Secretary of Harrison.ai, an Australian health tech AI company on a mission to transform global healthcare. Harrison.ai develops AI diagnostic assist tools for healthcare providers globally. Jen has over 13 years of experience in the legal industry and prior to joining Harrison.ai was a senior private M&A lawyer at Gilbert + Tobin, with a sector focus on technology. Jen is also a Baker McKenzie alumna of its Sydney Corporate practice.
Toby Patten, Partner, Australian Healthcare and Life Sciences Group, Baker McKenzie
Toby Patten is a partner in the Australian Healthcare and Life Sciences Group and a member of the Asia Pacific Healthcare and Life Sciences Leadership Committee. Toby also holds a Bachelor of Science in biochemistry. He advises and regularly presents to healthcare clients on privacy, clinical trials, healthcare regulatory, digital marketing and contractual issues.
MODERATOR
Elisabeth White, Partner, Baker McKenzie
Elisabeth White is a partner in Baker McKenzie's Sydney office and leads the Firm’s Healthcare and Life Sciences Group in Australia. Elisabeth has over 20 years' experience as an intellectual property and regulatory advisor, and holds a Master’s degree in bioethics.
Elisabeth advises market leading healthcare and life sciences companies in relation to a broad range of regulatory and IP matters and related disputes including: medical device and pharmaceutical regulation, advertising and promotional activities, interactions with patients, consumers and healthcare professionals, engagement with the TGA, adverse events and recalls, pricing and reimbursement. Elisabeth also has extensive experience handling contentious IP matters, including Australian Federal Court litigation concerning patents, trademarks, passing off and trade practices issues.
Notes
*Competitor Exclusion – ACC Australia Partner’s may request that representative/s of a competitor organisation/s registered for the event be excluded, and ACC Australia reserves the right to make the final decision as to whether a registration is rejected. As a guide, a competitor organisation could be defined as a rival organisation of similar size to the host Corporate Partner, with an established practice, product or service in the area being showcased by the Corporate Partner’s at the event. Please provide a brief statement as to why you have deemed an organisation to be a competitor, in support of any request to ACC Australia to reject a registration.
CLE
Sponsored By
